Skip to content

Clinical efficacy study of neoadjuvant therapy based on hepatic artery infusion chemotherapy for CNLC stage ?b-?b liver cancer

Clinical efficacy study of neoadjuvant therapy based on hepatic artery infusion chemotherapy for CNLC stage ?b-?b liver cancer

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2500107132
Enrollment
Unknown
Registered
2025-08-05
Start date
2024-05-01
Completion date
Unknown
Last updated
2025-08-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

hepatocellular carcinoma

Interventions

Simple hepatectomy group:none

Sponsors

Zhongshan People’s Hospital(Affiliated Zhongshan Hospital of Sun Yat-sen University)
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 75 Years

Inclusion criteria

Inclusion criteria: 1. Voluntarily sign informed consent; 2. From July 2017 to December 2023, he was admitted to Zhongshan People's Hospital; 3. The first diagnosis was CNLC stage ?b—?b liver cancer; 4. Age >=18, <=75; 5. Physical condition ECOG score (PS) : 0-1; 6. Child-Pugh score 5-7; 7. No history of other malignant tumors; 8. He has undergone liver resection or TACE or HAIC or has been treated with drugs such as sorafenib;

Exclusion criteria

Exclusion criteria: 1. Previous history of hepatectomy; 2. Previous history of liver ablation; 3. Having a history of organ transplantation; 4. Other patients deemed unsuitable for participation in this study by the investigator;

Design outcomes

Primary

MeasureTime frame
Relapse-Free Survival;

Secondary

MeasureTime frame
Overall survival;Progression free surviva;

Countries

China

Contacts

Public ContactSun Qiang

Zhongshan People’s Hospital(Affiliated Zhongshan Hospital of Sun Yat-sen University)

sqchina@163.com+86 760 8988 0300

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026